TCR Peptide Therapy in Autoimmunity

1993 ◽  
pp. 635-641
Author(s):  
Arthur A. Vandenbark ◽  
George Hashim ◽  
Halina Offner
Keyword(s):  
Peptide Therapy

Rationale for a T Cell Receptor Peptide Therapy in Myasthenia Gravis

2003 ◽  
Vol 998 (1) ◽  
pp. 320-323 ◽  
Author(s):  
F. JAMBOU ◽  
M. MENESTRIER ◽  
I. KLINGEL-SCHMITT ◽  
S. CAILLAT-ZUCMAN ◽  
A. AÏSSAOUI ◽  
...  
Keyword(s):  
T Cell ◽  
Myasthenia Gravis ◽  
T Cell Receptor ◽  
Cell Receptor ◽  
Peptide Therapy

scholarly journals Tolerogenic insulin peptide therapy precipitates type 1 diabetes

2017 ◽  
Vol 214 (7) ◽  
pp. 2153-2156 ◽  
Author(s):  
Marie-Louise Bergman ◽  
Thiago Lopes-Carvalho ◽  
Ana-Catarina Martins ◽  
Fabio A. Grieco ◽  
Décio L. Eizirik ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Disease Onset ◽  
Osmotic Pump ◽  
Preventive Effect ◽  
Peptide Therapy ◽  
Pump Delivery

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.

T Cell Receptor Peptide Therapy for Autoimmune Encephalomyelitis: Stronger Immunization Is Necessary for Effective Vaccination

1994 ◽  
Vol 153 (2) ◽  
pp. 468-478 ◽  
Author(s):  
Yoh Matsumoto ◽  
Masanori Tsuchida ◽  
Haruo Hanawa ◽  
Toru Abo
Keyword(s):  
T Cell ◽  
T Cell Receptor ◽  
Cell Receptor ◽  
Autoimmune Encephalomyelitis ◽  
Peptide Therapy

Assembly of HIV-1 gag-proteins: A new target for antiviral peptide therapy?

Peptides 1992 ◽  
1993 ◽  
pp. 133-135 ◽  
Author(s):  
Susanne Modrow ◽  
A. v. Poblotzki ◽  
R. Wagner ◽  
H. R. Gelderblom ◽  
G. Pauli ◽  
...  
Keyword(s):  
Peptide Therapy ◽  
Gag Proteins ◽  
Antiviral Peptide ◽  
Hiv 1

scholarly journals Reply to “Tolerogenic insulin peptide therapy precipitates type 1 diabetes”

2017 ◽  
Vol 214 (7) ◽  
pp. 2157-2159
Author(s):  
Carolin Daniel ◽  
Benno Weigmann ◽  
Harald von Boehmer
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Regulatory T Cell ◽  
Preventive Effect ◽  
Peptide Therapy ◽  
Cell Conversion

In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3+ regulatory T cell conversion.

scholarly journals Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yohei Ueda ◽  
Akihiro Yasoda ◽  
Keisho Hirota ◽  
Ichiro Yamauchi ◽  
Takafumi Yamashita ◽  
...  
Keyword(s):  
Natriuretic Peptide ◽  
Murine Model ◽  
Skeletal Growth ◽  
Glucocorticoid Treatment ◽  
Peptide Therapy
Sign in / Sign up

Export Citation Format

Share Document